COMMUNIQUÉS West-GlobeNewswire

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases
09/12/2017
ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting
09/12/2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
09/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, [...]
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
09/12/2017
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 09, [...]
BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting
09/12/2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
09/12/2017
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RP6530 (tenalisib), [...]
Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium
09/12/2017
SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict ® are [...]
JDRF welcomes CRA review of diabetes denials
08/12/2017
TORONTO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- The 300,000+ Canadians and their families living with type 1 diabetes (T1D) across the country welcome today’s announcement that the Government of Canada and the Canada Revenue [...]
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
08/12/2017
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ) , a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for [...]
Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
08/12/2017
Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate SOUTH [...]
Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint
08/12/2017
Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original dosing regimen. The Day 28 Endpoint was less than or equal [...]
Adamas Announces New Employment Inducement Grant
08/12/2017
EMERYVILLE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced that the compensation committee of the company’s board of directors granted 64 new employees the option [...]
New Sensory Friendly Reading with Dogs Library Event - 12/13/17
08/12/2017
FULLERTON, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fullerton Cares Autism Foundation is teaming up with the Fullerton Public Library to provide a sensory friendly reading time where children of all needs can meet, [...]
Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017
08/12/2017
SAN RAMON, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE) would like to remind stockholders to vote their respective shares and support the business combination transaction with SELLAS [...]
Burcon Announces Board Change and Confirms No Material Undisclosed Information
08/12/2017
VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX: BU ) (NASDAQ: BUR ) (“Burcon” or the “Corporation”), announced that effective today, Mr. Matthew Hall has resigned as [...]
GENFIT: ADDITIONAL RESOURCES ALLOCATED TO THE LIQUIDITY AGREEMENT
08/12/2017
GENFIT: ADDITIONAL RESOURCES ALLOCATED TO THE LIQUIDITY AGREEMENT Lille (France), Cambridge (Massachusetts, United States), December 8, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at [...]
GENFIT : APPORT COMPLEMENTAIRE AU CONTRAT DE LIQUIDITE
08/12/2017
GENFIT : APPORT COMPLEMENTAIRE AU CONTRAT DE LIQUIDITE Lille (France), Cambridge (Massachusetts, Etats-Unis), le 8 décembre 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique engagée dans [...]
Micron Solutions, Inc. Designates Mr. E. P. Marinos as a Director Emeritus and Appoints Mr. Andrei Soran to its Board of Directors
08/12/2017
FITCHBURG, Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Micron Solutions, Inc. (NYSE American:MICR) (“Micron” or the “Company”), announced the retirement of Mr. E. P. (“Lou”) Marinos from the Company’s Board of Directors [...]
Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
08/12/2017
OTTAWA, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize [...]

Pages